Cytel, Evidence Value & Access, London, WC2B 4HN, UK.
Cytel, Evidence Value & Access, Rotterdam, 3012 NJ, The Netherlands.
J Comp Eff Res. 2023 Oct;12(10):e230046. doi: 10.57264/cer-2023-0046. Epub 2023 Aug 21.
Failure to adjust for effect modifiers (EMs) in indirect treatment comparisons (ITCs) can produce biased and uncertain effect estimates. This is particularly important for health technology assessments (HTAs), where the availability of new treatments is based on comparative effectiveness results. Much emphasis has been placed on advancing ITC methods to adjust for EMs, yet whether EMs are appropriately identified for the conduct of ITCs in the first place is unclear. To understand the extent of guidance and requirements for the selection of EMs for ITCs currently available and if and how this guidance is applied in practice, a series of pragmatic reviews of guidance documents from HTA and non-payer organizations, primary published ITC analyses, and prior HTA submissions in two indications (non-small cell lung cancer and psoriasis) was conducted. The reviews showed that current ITC guidance mainly focused on developing analytical methods to adjust for EMs. Some organizations, such as HTA bodies in the UK, France and Germany, recommended the use of literature reviews, expert opinion and statistical methods to identify EMs. No detailed guidance on the selection process or the appropriate literature review approach was found. Similar trends were identified through the database search and review of prior HTA submissions; only few published ITCs and submissions included information on the EM selection process which was either based on findings from the literature, trial subgroup analyses, or clinical input. No reference to a systematic selection approach was found. There is an urgent need to fill the guidance gap identified across the reviews by including a step in ITC guidelines on how EMs should be identified through systematic reviews, formal expert elicitation, and a quantitative assessment of the EM distribution. Researchers and manufacturers are also encouraged to improve transparent reporting and justification of their selection of EMs to allow for an independent review of the set of factors being considered for adjustment. Both will contribute toward reducing bias in the ITC results and ultimately increase confidence in decision-making.
未能在间接治疗比较(ITC)中调整效应修饰剂(EMs)可能会产生有偏差和不确定的效应估计。这在健康技术评估(HTA)中尤为重要,因为新治疗方法的可用性基于比较有效性结果。人们非常重视推进 ITC 方法以调整 EMs,但首先要确定 ITC 中是否适当地确定了 EMs。为了了解当前用于 ITC 的 EM 选择的指导和要求的程度,以及是否以及如何在实践中应用这些指导,对来自 HTA 和非付款方组织的指导文件、主要发表的 ITC 分析以及在两个适应症(非小细胞肺癌和银屑病)中的先前 HTA 提交进行了一系列实用的审查。审查表明,当前的 ITC 指南主要侧重于开发调整 EMs 的分析方法。一些组织,如英国、法国和德国的 HTA 机构,建议使用文献综述、专家意见和统计方法来确定 EMs。没有找到关于选择过程或适当文献综述方法的详细指导。通过数据库搜索和对先前 HTA 提交的审查也发现了类似的趋势;只有少数发表的 ITC 和提交的文件包含有关 EM 选择过程的信息,这些信息要么基于文献中的发现,试验亚组分析,要么基于临床输入。没有发现提到系统选择方法。有必要通过在 ITC 指南中包含一个步骤来填补审查中发现的指导空白,该步骤涉及如何通过系统综述、正式的专家征集以及对 EM 分布的定量评估来识别 EMs。还鼓励研究人员和制造商改进对 EM 选择的透明报告和论证,以允许对正在考虑调整的因素集进行独立审查。这两者都将有助于减少 ITC 结果中的偏差,并最终提高决策的信心。